- Androcur® (cyproterone acetate) is sold in more than 60 markets across Europe, Canada, APAC, MENA, and Latin America
- The acquisition leverages ADVANZ’s commercial and medical footprint in Europe, as well as its global distribution partner network
- The acquisition further strengthens ADVANZ’s global specialty brands portfolio
London, UK – 07/11/2023: - ADVANZ PHARMA Corp. Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital, and rare disease medicines in Europe, Canada, and Australia, today announced it expands its specialty brands portfolio with the signing of the acquisition of global rights of Androcur® from Bayer. The transaction is subject to customary regulatory filings and is expected to close in Q1 2024.
Androcur® is an anti-androgen therapy. It blocks the actions of male sex hormones (androgens) and reduces the amount of male sex hormones produced by the body. It also serves as a treatment in inoperable carcinoma of the prostate.*
ADVANZ PHARMA continues leveraging its commercial footprint and global partner network to bring specialty medicines to patients worldwide. The transaction follows the recent announcement on 18 October 2023 that ADVANZ PHARMA signed an agreement to acquire Progynova® and Cyclo-Progynova® in selected countries in LatAm from Bayer and closed its acquisition of the global rights to Tostran® from Kyowa Kirin.
* Indications vary by market, strength, and form. For local indications please check the local approved label.
About ADVANZ PHARMA
Partner of choice in specialty, hospital, and rare disease medicines
ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network. ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity.
For more information, please visit our Website or LinkedIn.
For media inquiries, please contact:
Courtney Baines
ADVANZ PHARMA
Tel: +44 7776 516979 Email: courtney.baines@advanzpharma.com
